Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2025-01-13 Share Issue/Capital Cha…
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - OCC 8 pages 22.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities, specifically options, by Orthocell Limited. It includes specifics such as the number of securities issued, issue dates, security descriptions, and references to previous announcements (Appendix 3B). The document is a formal notification of securities issuance rather than a financial report, earnings release, or management discussion. It fits the category of announcements regarding new share issues or capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (8222 characters) and content confirm it is a full notification, not just a brief announcement or a report publication notice.
2025-01-13 English
Third Consecutive Quarter of Record Revenue for Orthocell 3 pages 252.9KB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of Orthocell's financial performance for the December 2024 quarter, highlighting record revenue figures, growth percentages compared to previous quarters, and market expansion plans. It includes specific quarterly revenue numbers, comparisons to prior quarters, and discusses operational and strategic details such as product sales, market penetration, regulatory approvals, and cash position. The document is approximately 8,700 characters long, which is substantial and contains actual financial data and analysis rather than just a brief summary or announcement. It is not a full annual report but a quarterly update with financial results and business commentary. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-01-07 English
US FDA Application Submitted for Remplir as US Launch Nears 3 pages 201.1KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the submission of a U.S. FDA 510(k) regulatory application for clearance to commercially distribute a medical product called Remplir. It discusses the regulatory submission process, expected clearance timeline, market opportunity, and commercial launch preparations. There are no financial statements, earnings data, or detailed financial analysis present. The document is not a full financial report, audit report, or earnings release. It is an update on regulatory and commercial progress related to a product and the company's strategic plans. This type of announcement fits best under the category of Capital/Financing Update (CAP) as it relates to regulatory approval and market launch preparations which impact the company's capital deployment and commercial strategy. It is not a report publication announcement or regulatory filing in the fallback sense, as it contains substantive business update information rather than just a notice of report availability.
2024-12-18 English
Major Milestone with First Sales of Remplir in Singapore 3 pages 228.6KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the first sales of Orthocell's medical device Remplir™ in Singapore, along with details about the company's commercial expansion, regulatory approvals, and financial position. It contains no financial statements, detailed financial analysis, or regulatory filings. It is a corporate announcement focused on commercial milestones and market expansion rather than a formal financial report or regulatory filing. The document length is 8511 characters, which is substantial but the content is clearly a commercial update. Therefore, it fits best into the category of Capital/Financing Update (CAP), as it relates to company growth, market expansion, and financial positioning for product launch and sales growth.
2024-12-11 English
Application for quotation of securities - OCC 9 pages 24.0KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement by Orthocell Limited regarding the application for quotation of securities on the ASX. It details the securities issued as a result of options being exercised or convertible securities being converted, including numbers, issue dates, and descriptions. The document is a regulatory announcement related to securities quotation and issuance, not a financial report, earnings release, or management discussion. It is a formal regulatory filing to the stock exchange about securities quotation, fitting the category of Regulatory Filings (RNS). The document length is 9464 characters, which is consistent with a detailed regulatory announcement rather than a full financial report or presentation.
2024-12-09 English
Notification regarding unquoted securities - OCC 10 pages 27.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of new unquoted options as part of fees to a lead manager. It includes specifics about the securities issued, their terms, and compliance with ASX listing rules. The content is a formal notification of securities issuance rather than a financial report, earnings release, or management discussion. This type of document corresponds to announcements about share issues or capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback.
2024-12-02 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.